Deals Shaping The Medical Industry, April 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
Titanium dioxide - used as a colorant in many dietary supplements - is no longer considered safe when used as a food additive, says the European Food Safety Authority. The European Commission and EU member states must now decide whether to follow France's lead and ban its use in foods outright.
Sandoz has recruited Teva’s Karan Ambwani to head up the Novartis unit’s strategy, business development and portfolio in Europe. Meanwhile, Diane DiGangi Trench is moving from Sandoz US to head up the company’s operations in the UK.
Coherus BioSciences aims to have four biosimilars on the market by 2023, including ranibizumab and bevacizumab for which it has provided updated timelines for planned US Food and Drug Administration filings.